Skip to main content

And Nothing Else Matters...

We're at the point in the market where it feels like 'nothing matters' but, still, these stats should.

The Market

Since we will go up one percent a day every day from now until the end of time I should just leave this section blank.

But I cannot. The funny thing is that breadth, while good enough to make a new high, was worse Wednesday than Tuesday. So, basically, while the non-big cap tech stocks participated, they were not the leaders. Quite frankly, Wednesday's charts felt more like some were up and some were down, and it sure did not feel like the sort of day when the S&P 500 was up 21 and Nasdaq near 90. I guess Apple (AAPL:Nasdaq) had a lot to do with that.

Let me get to what might be relevant, though. We're at the point in the market where "nothing matters," but I feel compelled to share anyway. New highs fell short of Wednesday's readings, which is once again the pattern that we see, where new highs expand for one day, and that's that.

The Nasdaq Momentum Indicator will get overbought after trading on Thursday. I have walked it up 200 points in the next week (I usually do 200 points in two weeks but, hey, why not?). Take a look: No matter what happens, this peaks on Thursday. And it doesn't peak gently.

Image placeholder title

Along with that, let me note that the DSI for the Volatility Index is now 10. Single digits, and this has gone too far. Nasdaq's DSI is 85. One more up day, and this might get to 90.

I would also note for dollar bulls that the DSI for the Dollar Index is at 89 and the Euro is 9.

New Ideas

I am going to start with my new favorite stock to watch, Cummins (CMI) - Get Free Report, because it has now been up three straight days. It has resistance around that $170 area, but to me this remains a stock to focus on.

Image placeholder title

Teva (TEVA) - Get Free Report, a stock I have liked for months now, had a big gap up on volume Wednesday. This is a reminder that the base has a first measurement at $14 and the gap gets filled there. I'd look to take some profits. It just reported earnings.

Image placeholder title

Coupa Software (COUP:Nasdaq) bounced off support, so as long as it stays over that support area, it gets the benefit of the doubt. It's slated to report next month.

Image placeholder title

Today's Indicator

The Volume Indicator is stuck at 50%.

Image placeholder title

Q&A/Reader’s Feedback

Helene welcomes your questions about Top Stocks and her charting strategy and techniques. Please send an email directly to Helene with your questions. However, please remember that TheStreet.com Top Stocks is not intended to provide personalized investment advice. Email Helene here.

Abbott Labs (ABT) - Get Free Report hasn’t really done anything wrong yet except that it hasn’t made a new high yet. But as long as it stays over this $87 area, this move looks like it’s just a correction.

Image placeholder title

I am not a huge fan of the gold stocks right here, so when I look at Anglogold (AU) - Get Free Report I can’t decide if it will hold $18 and curl under and this entire sideways move since August will become a base, or if it will break $18 and become a top. Either way $18 is clearly a line in the sand. AU is slated to report earnings later this month.

Image placeholder title

CrowdStrike (CRWD:Nasdaq) is a chart I have liked for a while and quite frankly it spends a lot of time teasing and not rallying. But if it can ever get going, it would be a nice breakout, wouldn’t it? The company is slated to report late next month.

Image placeholder title

Hain Celestial (HAIN:Nasdaq) has a measured target of $27.50-$28.50, so it doesn’t have a lot more upside. If it pulled back near $26, I think it would be worth a chance on the buy side.

Image placeholder title

Navient (NAVI:Nasdaq) has a measured target around $16-$17. What I would like to see is the stock do some sideways work between $14-$15, so that it has some oomph when it is ready to go again. Right here it looks to me like it could peter out right near the highs.

Image placeholder title

Nutanix (NTNX:Nasdaq), which is slated to report later this month, has an unfulfilled target near that blue line. That would be the next target, especially if it can get through that December high around $37.50. I am fond of this chart.

Image placeholder title

Nektar Therapeutics (NKTR:Nasdaq) is a funky chart. It had a terrific run to fill the gap, came back more than it should have (should have stopped near $22) and broke the uptrend line and is on the move again. For now I’m inclined to think that spike high in the $27-$28 area is the best it can do since there is a lot of resistance all the way up through the mid-$30s. It's slated to report later this month.

Image placeholder title
Dow is the Most Vulnerable to Profit Taking

Dow is the Most Vulnerable to Profit Taking

Despite the newfound focus on the Dow Jones Industrial Average last week, it turns out we may be seeing the last gasp of outperformance here.

How Hungry Is This Market?

How Hungry Is This Market?

Here's what I'd like to see happen with this rally -- I'd like it to show some FAANGs. Here's why -- and a look at Microsoft's chart, news highs and more.

Sloppy With a Chance of Rallying

Sloppy With a Chance of Rallying

Here's why I see another rally before the weekend, even amid the messiness, and a bump for Amazon.

Sloppy With a Chance of Rallying

We Can Rally Just a Bit More

Energy stocks have a lot of complacency in them.